Phase 1 Ovarian Cancer Trial, Recruiting NCT06469281 Sponsor: Regeneron Pharmaceuticals Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 1 Ovarian Cancer Trial, Recruiting

NCT06469281
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be well enough to carry out some daily activities, with only mild limitations caused by your illness (based on a standard health performance scale).
  • You must have been diagnosed with a specific type of cancer affecting the ovaries, the lining of the abdomen, or the fallopian tubes, confirmed by a tissue sample.
  • Your cancer must have come back or stopped responding to previous treatment, as described in the trial guidelines.
  • A specific protein marker in your blood (CA-125) must be at least twice the normal upper limit, measured by an approved blood test during screening.
  • You must have at least one measurable tumor that can be tracked using standard medical imaging guidelines.
  • You must be expected to live for at least 3 months.

Who may not be able to join:

  • You may not be eligible if your heart, kidneys, or liver are not functioning well enough, as defined by the trial guidelines.
  • You may not be eligible if your immune cell count (a type of white blood cell) is too low at the time of a blood collection procedure called leukapheresis.
  • You may not be eligible if you have had significant bleeding in the last 30 days, or if your blood does not clot properly, as described in the trial guidelines.
  • You may not be eligible if you have a known history of certain significant brain or nervous system conditions, as described in the trial guidelines.
  • You may not be eligible if you have had a significant autoimmune disease requiring treatment with immune-suppressing medicines within the past 2 years.
  • You may not be eligible if you have previously received any cell-based or gene therapy treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
6 August 2024
Est. completion
27 May 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of treatment emergent adverse events (TEAEs); Incidence of adverse events of special interest (AESIs); Incidence of adverse events of dose limiting toxicities (DLTs); Manufacturing feasibility of 27T51; Overall response rate (ORR) as assessed by the investigator

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov